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Abstract
The antiphospholipid syndrome (APS) is an autoimmune disease characterised by a procoagulant state that
predisposes to recurrent thrombosis and miscarriages. Two major discoveries have advanced our understanding of
the underlying complex pathogenesis of the APS. The first was the discovery that beta-2 glycoprotein-1 (β2GPI) is
the major auto antigen in APS. The second was the discovery in more recent years that β2GPI contains allosteric
disulphide bonds susceptible to posttranslational modification that may be involved in the development of
autoantibodies in APS. The main allosteric disulphide bond in the fifth domain of β2GPI can exist in two redox
states: free thiol or oxidised. It is the conformational transformation of β2GPI from its free thiol form to its more
immunogenic oxidised form that exposes neo-epitopes on the first and fifth domains. The purpose of this review is
to highlight the recent findings on the posttranslational forms of β2GPI in the pathogenesis of APS. We suggest
that novel assays quantitating the different redox forms of β2GPI in plasma or serum may be used to supplement
existing clinical and laboratory assays to more accurately stratify risk of thrombosis or miscarriage in APS patients.
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Background
Antiphospholipid syndrome (APS) is an autoimmune
disease and a major cause of acquired thrombophilia. It is
characterised by a hypercoaguable vascular compartment
due to the persistent presence of antiphospholipid
antibodies (aPL), detected by either one of the following
assays: in vitro coagulation assay lupus anticoagulant (LA),
and/or solid phase assays anticardiolipin (aCL) and/or
anti-beta 2-glycoprotein I (anti-β2GPI) [1, 2].
APS has two main manifestations: thrombotic or
obstetric [3]. The hallmark feature of thrombotic APS is
arterial or venous thrombosis, most commonly stroke
and/or lower limb venous thromboembolism. Obstetric
APS presents as recurrent first trimester miscarriages,
and second trimester foetal death and obstetric compli-
cations such as early onset severe preeclampsia. APS can
be associated with other autoimmune diseases such as
systemic lupus erythematosus (SLE). In rare cases this
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syndrome can develop into an often fatal manifestation
known as catastrophic APS, characterized by thrombotic
microangiopathy in multiple concurrent vascular beds.
Review
Diagnosis and treatment of APS
Renewed efforts to understand the pathogenesis and
streamline the diagnosis and treatment regimen has
been the focus of clinicians and researchers in the field
globally [4]. Current consensus is to diagnose APS using
a combination of laboratory and clinical criteria [2, 5].
APS classification is made when two serological tests
12 weeks apart return positive for persistent levels of
lupus anticoagulant (LA), or high titres anticardiolipin
(aCL) and/or anti-β2GPI antibodies in combination with
a history of a thromboembolic event or miscarriages [6].
There is no single treatment for APS. The gold standard
therapeutic management comprises of antiplatelet and
anticoagulant agents, although no consensus exists on the
finite duration and intensity regimen as reviewed in [5, 7].
Corticosteroids, plasma exchanges are also considered in
patients presenting with catastrophic APS [8].
Beta 2-glycoprotein I is the major autoantigen in APS
β2GPI, also known as apolipoprotein H, is the main
autoantigen in APS [9]. It mediates the binding between
aPL and phospholipids. It was previously thought that
aPL bound directly to phospholipids resulting in the
inaccurate naming of this syndrome [9]. aPL only
recognise β2GPI when it is bound to phospholipids as
cryptic epitopes become exposed following binding.
Beta 2-glycoprotein I biology
β2GPI is important in the pathogenesis of the APS, but
its precise physiological function in vivo is still being
delineated [10, 11]. There is evidence to show that it
regulates complement [12], inhibits procoagulant factors
such as factor XI/XIa and thrombin [13–15]. It inhibits
angiogenesis [16, 17] and interacts with components of
the atherosclerotic plaque such as apolipoprotein(a) [18].
It interacts with the platelet receptor glycoprotein Ib-IX-V
[19] and with von Willebrand Factor (vWF) [20]. It also
interacts with endothelial cells [21, 22] and apoptotic cells
[23]. β2GPI is also involved in the innate immune response
and plasma levels drop during the acute phase of infective
inflammation [24]. It also plays a role in early embryonic
development and is important for implantation success in
mice [25]. β2GPI can interact with apolipoprotein E
receptor 2 (APOER2), a member of the low-density
lipoprotein (LDL) receptor family as well as annexin V and
II on cell membranes of platelets, endothelial cells and
monocytes [26–28].
β2GPI is synthesised in the liver and can localise on
the endothelium of uterine vessels and the site of
implantation in pregnant mice [29]. There is some
evidence for β2GPI expression in the intestines of rats
and mice and low expression in rat kidney, heart, brain,
spleen, stomach and prostate [30, 31]. However, only
following priming with lipopolysaccharide (LPS) does
β2GPI localise on cerebral, cardiac and intestinal
endothelial cells [29]. It can be detected at the site of injury
within the retina of patients with age-related macular
degeneration (AMD) [32] and the myocardium of mice
subjected to ischemia reperfusion injury (IRI) [33].
The absence of β2GPI modulates the autoimmune
phenotype in SLE prone mice in which toll like receptor
7 (TLR7) plays a major role [34]. In a mouse model of
systemic lupus, deletion of β2GPI increased the levels of
autoantibodies, inflammatory cytokines and the presence
of lymphadenopathy and splenomegaly [34]. In a mouse
model of cardiac IRI, damage is reduced by treatment
with the fifth domain of β2GPI [33]. Treatment with the
fifth domain of β2GPI also reduced neutrophil and
monocyte infiltration in the area at risk following
reperfusion [33]. Domain V offers potential as a therapy
in cardiac IRI by acting as a universal inhibitor of the
initial inflammatory cascade by blocking the binding of
pathogenic natural IgM antibodies to cardiac neoepitopes
exposed during reperfusion [33].
Structural conformations of Beta 2-glycoprotein I
Human β2GPI is highly conserved and has high
structural homology between species [35]. It consists of
five domains, domain I at the N-terminus through to
domain V at the C-terminus. These domains are also
known as short consensus repeats (SCR), sushi domains
or complement control proteins. The first four domains
are made up of 60 amino acid residues with the fifth
domain having an extra 26 amino acid loop. β2GPI has
11 disulphide bonds in total, two disulphide bonds per
domain except for the fifth domain that contains an
extra disulphide bond.
The fifth domain is exceptionally important as the
extra disulphide bridge within it participates in the
preferential binding of negatively charged phospho-
lipids on activated cell membranes [36, 37]. The unique
structural feature of domain V is the aberrant fold
made of a six-residue insertion and a 19-residue exten-
sion C‐terminally cross‐linked by an extra disulfide
bond between Cys288-Cys326 [36, 38]. There are two
main reasons for the unique phospholipid membrane
binding specificity of the fifth domain. Firstly, the fifth
domain has a positively charged patch. Secondly, it has
a flexible partially hydrophobic insertion loop that
inserts into the lipid layer and uses Trp316 to anchor
into the membrane. This insertion loop is highly con-
served across the entire animal kingdom suggesting its
physiological importance [35].
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Posttranslational modification of Beta 2-glycoprotein I
The extra disulphide bond Cys288-Cys326 in the C
terminal domain is allosteric and mediates a func-
tional change of the protein following posttransla-
tional modification [20, 39]. β2GPI has naturally
occurring free thiols in vivo and the catalytic disulphide
bonds found in oxidoreducatses can control the redox
state of this bond [40, 41]. This allosteric disulphide bond
influences the structure and function of β2GPI.
β2GPI is a thiol oxidoreductase substrate and its
cysteine residue (Cys288–Cys326) within the fifth
domain is able to form free thiols following incubation
with oxidoreducatase enzymes thioredoxin-1 (TRX-1)
and protein disulphide isomerase (PDI) [40]. Thiol
oxidoreductases are important in platelet and endothelial
cell function [40, 42].
It has been proposed that β2GPI has a major role in
the pathogenesis of APS due to its susceptibility to
posttranslational oxidative modification by reactive
oxygen species and the subsequent exposure of
neoantigens [3]. β2GPI protects endothelial cells from
oxidative stress-induced cell death [41] and promotes
platelet vWF interactions in vitro [20]. Under oxidative
stress, free thiol β2GPI undergoes posttranslational
modification through oxidation and/or nitrolysation of
the redox sensitive cysteine residues [43]. The addition
of oxygen or nitrogen oxide (NO) to cysteines can alter
the function of β2GPI and increase its immunogenicity.
Oxidative modification of β2GPI at supraphysiological
concentrations of oxidant has been implicated in pro-
moting helper type 1 T cell responses and inducing the
maturation of monocyte-derived dendritic cells [44].
Following posttranslational modification, β2GPI under-
goes conformational change that exposes the major B-cell
binding site on domain I and the major T-cell binding site
on domain V. Thus, the proportion of free thiol β2GPI and
oxidized β2GPI is important to the development of anti--
β2GPI autoantibodies in APS. Domain 1 and V are
required to elicit the generation of pathogenic aPL [3].
Although no direct structural or spectroscopic data
demonstrating a conformational change following post-
translational modification of β2GPI have been reported,
affinity purified anti-β2GPI autoantibodies from patients
with APS bind oxidised-β2GPI at a higher avidity than the
free-thiol form [3].
Pathogenic aPL recognise domain I only after the
conformational change [45]. Recombinant domain I of
β2GPI can inhibit thrombus formation in vivo in a
mouse model of anti-β2GPI induced potentiation of
mechanical induced thrombosis [46].
Oxidised Beta 2-glycoprotein I a biomarker for APS?
Quantitation of oxidised APS could be useful as a
biomarker of APS. The levels of total β2GPI in serum of
APS patients are elevated compared to patients with
other autoimmune diseases, thrombosis or healthy
controls [39, 47]. These levels are only elevated in
patients positive for persistent aPL with a history of
thrombosis [39]. The proportion of protective free
thiol β2GPI in APS patients is low compared to pa-
tients with other autoimmune diseases. Free thiol
β2GPI may be protective and the lower levels indicate
a higher proportion of oxidised β2GPI [39].
Current classification criteria do not enable stratifi-
cation of thrombotic risk. Detection of thiol-exchange
reactions, the posttranslational modification of β2GPI
could supplement current diagnostic tools for APS
and accurately predict risk of thrombosis in APS [39].
In vitro assays screening samples to stratify thrombosis
risk, could also be modified to assay for free thiols in other
diseases where the redox-state of β2GPI is an important
player such as age related macular degeneration [32]. Dir-
ectly quantifying the various redox states of β2GPI is a
unique and novel approach for delineating the relationship
between autoantigen redox state and disease severity [39].
We have developed two β2GPI enzyme-linked
immunosorbent assays (ELISA) one measuring the
total level of β2GPI and the other the proportion of
free thiol β2GPI in human plasma and serum. Free
thiol β2GPI is quantified using a biotinylated probe
that is specific for free thiols. Following addition of
this probe to plasma or serum, the unincorporated
biotinylated probe is removed by an acetone precipi-
tation step and biotinylated proteins are specifically
captured on a streptavidin ELISA plate. A monoclonal
anti-β2GPI antibody quantifies the amount of β2GPI with
biotinylated free thiols that have been captured on the
ELISA plate [39]. From these assays we are able to deduce
the proportion of β2GPI in an oxidised state [39]. Quanti-
fication of β2GPI and its post-translational forms can sup-
plement existing prognostic and diagnostic protocols to
better stratify thrombotic risk in APS patients.
Conclusions
Oxidized β2GPI may be a useful specific prognostic marker
for APS and enhance our management of APS patients. In
a retrospective multicenter international study we
demonstrated that patients with thrombotic APS have
higher levels of oxidized β2GPI compared to healthy indi-
viduals and patients with other autoimmune conditions
[39]. β2GPI is susceptible to cleavage by oxidoreductases
that circulate in human plasma and reduce the cysteines to
free thiols. These free thiols can be quantified using a novel
ELISA assay we have developed and may be useful in the
diagnosis of aPL antibody positive patients presenting with
no clinical event or in stratifying the risk of a thrombotic
event in patients with APS.
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